tween the 3 groups, so that a statistical probability of the presence of malignancy is available from the test. With slowing values below 250/% there is little likelihood of cancer. Tumour type influences the test result, as does, to a lesser extent, tumour bulk.
VARIOUS ASSAYS have been reported as detecting the release of lymphokines when lymphocytes sensitized to tumour antigens are exposed to an appropriate tumourantigen preparation, or to myelin basic protein (e.g. Moore & Lajtha, 1977; Pick, 1977) . The assay which has generated the greatest degree of controversy is, perhaps, the Macrophage Electrophoretic Mobility (MEM) test of Field & Caspary (1970) . This is dependent upon a decrease in the electrophoretic mobility of macrophages when these have been incubated with lymphocyte supernatants containing the lymphokine Macrophage Slowing Factor (MSF). The test is technically very demanding, and is very sensitive to the quality of the guinea-pig peritoneal exudates (Dickinson & Dyson, 1978) which are the source of the macrophages required for the test. Possibly because of this, the question of the validity of the test as an assay for sensitized lymphocytes, and especially as a method for detecting malignant disease, has never been entirely resolved. Some have reported confirmation of the results of Field & Caspary (1970) (e.g. Pritchard et al., 1972 Pritchard et al., , 1973 Preece & Light, 1974; Rawlins et al., 1976) . Others, however, have been unable to confirm their results (e.g. Crozier et al., 1976; Arvilommi et al., 1977; Forrester et al., 1977) . In a recent study using laser Doppler electrophoresis, Petty et al. (1980) found that guinea-pig lymphokines reduced the electrophoretic mobility of guinea-pig macrophages by some 15%, but were unable to detect any effect of human lymphokines.
In an attempt to eliminate the problems associated with guinea-pig macrophages, Porzsolt et al. (1975) reported that sheep erythrocytes, treated with tannic acid and stabilized with sulphosalicylic acid, could be used as indicator cells in the MEM test. We were able to reproduce their results and, in an initial trial, found the test system to detect the presence of malignancy with a success rate of some 80% (Dyson & Corbett, 1978) . However, we differed from Porzsolt et al. (1975) who reported their test system as a modification of the MEM test, which is generally accepted as having an immunological basis (Dickinson, 1979) , in considering the test using tanned erythrocytes to be nonimmunological, and depending on the alteration of a physiological factor in the presence of malignancy (Dyson & Corbett, 1978) . Further work has supported the view that, rather than a lymphokine being involved, the inhibition of the electrophoretic mobility of the tanned erythrocytes is due to neutralization of their negative change on binding myelin basic protein (the antigen used in the test), the inhibition being further increased by histones present as an impurity (Dyson & Watkinson, submitted for publication) . The affinity of the myelin basic protein and histones for the erythrocytes is gradually lost on incubation with lymphocytes, due to degradation of these proteins by a proteolytic enzyme on the lymphocyte surface (Dyson, submitted for publication). The activity of this enzyme is reduced in subjects with malignant disease, thus the degradation of the myelin basic protein and histones is reduced, and they partially retain their affinity for the tanned erythrocytes, and, therefore, their effect on electrophoretic mobility (Dyson, 1979) . This partial retention of electrophoretic mobility inhibition when the preincubation is with lymphocytes derived from cancer patients gives the impression of the effect of MSF. However, Ax (1979) has recently reported that an antigen may be isolated from human brain extract that, while not directly affecting erythrocyte electrophoretic mobility, yet causes release of a lymphokine capable of reducing their mobility.
Since our first report (Dyson & Corbett, 1978) a double-blind trial has been in progress to determine the ability of the method to distinguish between normal subjects, those with disease other /than cancer, and patients with malignant disease. A sufficient number of subjects have now been incorporated in the trial for preliminary conclusions to be reached regarding the discriminatory ability of the test, and for experience to be gained in the factors which influence the reliability of the test, both those inherent in the test subject and those due to the test system. The results for the 360 subjects included in the test, together with a preliminary analysis of some of the factors which influence the test, are therefore presented in this report.
MATERIALS AND METHODS
Selection of subjects.-At this stage in the investigation our object was only to determine the ability of the test to discriminate subjects with known malignant disease from normal control subjects, and from those with disease other than cancer, and also to attempt to assess to what extent tumour site, tumour bulk and degree of tissue invasion influenced the test results. The only criterion applied at this time to the selection of cancer patients for inclusion in the trial was, therefore, that a malignant tumour had been diagnosed, and that radiotherapy or chemotherapy had not begun. No effect of the age of the subject on the test result has been detectable in any of the 3 groups, so age-matching controls to cancer patients has not been attempted at this stage.
The method of coding throughout the investigation was as follows. A number was allocated to each donor in the clinic where the blood sample was taken. The records matching each number with name and diagnosis were not released until the end of the trial. During preparation of the incubation mixtures new numbers were allocated in the laboratory for that day's blood samples. Thus, the operator was unaware which incubation mixture corresponded to which blood sample when electrophoretic measurements were carried out.
Preparation of lymphocytes.-Defibrinated blood was used throughout the investigation. The collection of blood samples and isolation of lymphocytes (Dyson & Corbett, 1978) was unchanged, with the exception that Lymphocyte Separation Medium (Flow Laboratories, Irvine, Ayrshire) replaced Ficoll-Paque for the latter part of the investigation. No difference in lymphocyte recovery, or in results, were observed when the 2 media were compared. Hanks' balanced salt solution (HBSS) replaced Eagle's Basal Medium (BEM) for final suspension of the lymphocytes.
Brainl extracts. Extracts of hurman brain (BE) were prepared essentially as previously described (Dyson & Corbett, 1978 
RESULTS

The double-blind trial
The residual slowing values for the 360 subjects included in the trial are shown in Fig. 1 , separated into 6 categories. Category A includes all normal controls. These were fit, healthy subjects with no known disease, principally hospital staff, and relatives of patients attending clinics at Cookridge Hospital. Category B subjects were those with diseases other than cancer, selected from several different clinics. The diagnoses for those subjects in whom the residual slowing value exceeded 3000, are shown in Table I Table 11 presents a statistical analysis of the data of Fig. l , including values for the t test for independent means and the corresponding P. The percent probability of exceeding a given slowing value is shown plotted in Fig. 2 for Categories A to F (omitting Category C), these values being derived from normalized curves calculated from the data for the separate categories shown in Fig. 1 . In Categories E and F (Fig. 1) tables of Fisher & Yates (1970) were used to obtain the values in Table II and Fig. 2 .
Factors influencing residual slowing Fig. 3 shows the residual slowing as a function of lymphocyte number of a normal subject tested at 3-weekly intervals over 9 weeks. In the absence of a viral infection such values are typical of normal control subjects when a satisfactory BE preparation is used. On viral infection, test values increase 2 to 3 days before clinical symptoms are evident and then decline, returning to normal within 2-4 weeks. Reproducibility of results for subjects with malignant disease has been more difficult to assess, as patients start therapy after the initial test, and the effect of this on subsequent test results cannot be separated from experimental variation. However, several patients are at present being followed on completion of therapy and, although slowing values differ from patient to patient, the reproducibility at 2-3-week intervals is comparable to that for normal subjects.
On replicate determinations with separate blood samples taken from the same donor on the same day, and processed in parallel, the standard deviation never exceeded 7%, the same order of magnitude Lymphocyte number x 106
FIa. 3. Reproducibility of residual slowing values for a normal control subject over a 9-week period. Tested at 3-weekly intervals on dates shown in Figure. Slowing values as function of lymphocyte number. BE 1 mg/3 ml, 18h incubation. Bars show s.d.
as the standard deviation in the determination of individual slowing values. During the double-blind trial several different preparations of BE were used, some yielding better differentiation between cancer patients and normal controls than others. There appear to be 2 principal reasons for this: (i) the addition of 5 x 106 lymphocytes to 1 mg/3 ml of the BE preparation used in Fig. 3 Pritchard, 1979) . It is not yet apparent why the other diseases in Table I For Category E and F cancers ( Fig. 1 ) slowing exceeding 5000 definitely appears to be associated with malignancy (Fig. 2) .
For slowing values between 25 and 50%0, however, a statistical probability only can at present be assigned to the possibility of malignancy (Fig. 2) , the degree of confidence depending on the extent to which certain diseases other than cancer, which also give high values, can be eliminated.
For slowing less than 25% there is little statistical probability of cancer (Fig. 2) Included in the double-blind trial were many patients who had undergone radiotherapy or chemotherapy subsequent to surgery. The extent to which these subjects were free of microscopic tumour is not known, and will not be evident for some time. Thus, the time taken for test values to revert to normal when the subjects are free of tumour is not yet known.
Careful follow-up of selected groups of cancer patients will show us whether this test can be of use for prognosis in these situations.
